Cancer Studies - Targeted Chemotherapy on ovarian and breast cancers

ChemoFx^® is supported by published peer-reviewed clinical studies, ongoing trials with cooperative groups, and a commitment to additional research. As you'll discover in the charts below, in vitro response correlates with clinical outcomes, so you can have increased confidence that your patients are likely to respond to the treatments you choose.^1-4

Ovarian Cancer Studies

Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay.²

Results correlate significantly with Progression-Free Interval (PFI).²

Progression-free interval chart - response category

ChemoFx^® results were evaluated to determine the association between prediction of response to chemotherapy and PFI in ovarian cancer.²

ChemoFx^® results correlate with PFI; patients treated with an assay-responsive drug had a PFI 2.9 times longer than patients treated with an assay-non-responsive drug.

Chemosensitivity testing with ChemoFx^® and overall survival in primary ovarian cancer.⁵

Results correlate significantly with overall survival (OS).⁵

ChemoFx^® results were evaluated to determine the association between prediction of response to platinum therapy and overall survival after first-line platinum-based chemotherapy in patients with advanced-stage primary ovarian cancer.⁵

Overall survival chart - response category

Findings showed:

Patients treated with an agent deemed responsive by ChemoFx^® had an OS >2.5 times longer than patients treated with a drug categorized as non-responsive by the marker
35 (90%) of the 39 patients whose tumors tested non-responsive to the therapy that the patient actually received had a more responsive alternative, noncrossresistant drug identified by ChemoFx^®
ChemoFx prediction of response to platinum therapy was consistent with expected population response rates

*Published data indicate median overall survival for patients treated with platinum/taxane therapy is 47 months.^4,6-8

Breast Cancer Study

Demonstrating the clinical utility of ChemoFx^® in breast cancer.³

Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients.³ Findings showed:

The test was successful in 84% of specimens using tissue samples as small as 35 mg, equal to two core biopsies
Chemoresponse profiles were highly reproducible with variability of <3%
Results for docetaxel/capecitabine response correlated with pathologic complete response (pCR); a cross-validated model showed 75% accuracy
It is feasible to assess the chemoresponsiveness of even the smallest breast lesions using ChemoFx^® to assist in choosing neoadjuvant chemotherapy for breast cancer patients

In addition to the studies above, click the link below to access a bibliography where other studies are detailed: Precision Bibliography

'ChemoFx® has the potential to predict which chemotherapy regimens will be most effective, thus potentially sparing patients from unnecessary toxicity associated with ineffective treatment...' -Joyce O'Shaughnessy, MD, of Baylor-Sammons